Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Researchers discover LSD-1 enzyme as important target for treatment of Ewing sarcoma

Discovery of a new drug with high potential to treat Ewing sarcoma, an often deadly cancer of children and young adults, and the previously unknown mechanism behind it, come hand-in-hand in a new study by researchers from Huntsman Cancer Institute (HCI) at the University of Utah. The report appears in today's online issue of the journal Oncogene.

26 Nov 2012

Two new studies explore how laws, advertising impact cancer costs

Reuters reports on two new studies regarding cancer treatment costs, including findings that laws don't curb the use of pricey prostate cancer treatments and that ads don't increase the use of aromatase inhibitors for breast cancer.

26 Nov 2012

mRNA vaccines offer protection against influenza A virus infections in various animal models

CureVac GmbH, a clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, and the German Federal Research Institute for Animal Health, Friedrich-Loeffler-Institute (FLI), Germany, today announced that mRNA vaccines (RNActive) based on the company's RNA technology platform have the potential to provide effective protection against infectious diseases.

26 Nov 2012

Factors influencing pain in head and neck cancer patients clarified

Individuals with head and neck cancer frequently report pain 1 year after diagnosis, despite being treated with analgesics, show US study results.

22 Nov 2012

Homing beacon drugs can kill cancer cells

A medical researcher with the University of Alberta and his team just published their findings about their work on developing 'homing beacon drugs' that kill only cancer cells, not healthy ones, thanks to nano-technology.

22 Nov 2012

Exercise relieves cancer fatigue

A review of studies spanning 45 years shows that exercise, particularly aerobic rather than strength- or flexibility-based training, improves fatigue in cancer patients.

21 Nov 2012

Fujirebio, Thermo Fisher sign license agreement for broad availability of PCT testing

Thermo Fisher Scientific Inc., the world leader in serving science, today announced it has signed a long-term license agreement with Fujirebio Inc. to make its biomarker assay Procalcitonin (PCT) available on the Lumipulse family of laboratory instruments, using the chemiluminescent enzyme immunoassay (CLEIA) technology.

From Thermo Fisher Scientific Inc. 21 Nov 2012

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

Janssen-Cilag International NV (Janssen) announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of the oral, once-daily medication ZYTIGA for use in combination with prednisone or prednisolone in the treatment of metastatic castration-resistant prostate cancer (mCRPC), in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated.

19 Nov 2012

Postprostatectomy urinary function assessment tool refined

Researchers have presented a proposed stratification of the urinary incontinence domain of the Expanded Prostate Cancer Index Composite.

19 Nov 2012

EMUC discusses current and future prospects in imaging for prostate cancer

At the 4th European Multidisciplinary Meeting on Urological Cancers (EMUC) held this weekend in Barcelona, Spain, specialists from radiology, urology, medical oncology and pathology said that new developments and research are already underway but benefits to patients would take some time due to the need for clinical trials, the high cost of funding research and the ability of cancer experts to efficiently take advantage of new insights and approaches, among other challenges.

19 Nov 2012

Loyola explores different prostate cancer websites for meaningful medical information

Prostate cancer, like many medical conditions, varies in presentation, treatment options, and outcomes. Undeniably, patients rely on the Internet for early education about their prostate cancer diagnosis or to fill information gaps from doctors. We use the Internet to research nearly every facet of our lives, and our physical wellbeing is no exception. But can we trust what we read? Better yet, can we understand it?

17 Nov 2012

Peak interest in health issues comes at about age 51 for baby boomers

For baby boomers, the peak interest in health issues comes at about age 51, with a second peak coming near age 65, according to a new study.

16 Nov 2012

Adequate pain management at end of life is a team effort

Inadequate management of pain in patients with terminal illness and those at the end of their lives exists because of knowledge deficits and misperceptions among patients, families, and healthcare providers, indicate the results of a study involving palliative nurses.

15 Nov 2012

Promising new minimally toxic approach to treat solid tumors with radiation

A promising new approach to treating solid tumors with radiation was highly efficacious and minimally toxic to healthy tissue in a mouse model of cancer, according to data published in Cancer Research, a journal of the American Association for Cancer Research.

15 Nov 2012

Simple ways to reduce risk of lung cancer

More than an estimated 160,000 people in the United States will die from lung cancer this year, making it the country's leading cause of cancer death. According to the National Cancer Institute, it surpassed breast cancer as the number one killer in women back in 1987. It causes more deaths than colon, breast and prostate cancer combined, according to the American Lung Association. Bruce Johnson, MD, the director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, sorts out the facts about lung cancer and offers simple ways to reduce risk.

15 Nov 2012

Viruses to treat metastatic cancers

There exists a "type" of cancer that is common yet rarely discussed—metastatic cancer, or cancer that has spread from the part of the body where it originated (the primary tumor) to another (such as lungs, bones or liver). Although much research is being done to combat primary tumors, there still exists a crucial need to find a treatment that can be effective against metastatic cancer, or "mets." Could a virus be the answer that finally beats the mets?

15 Nov 2012

Palliative care advice for dementia ‘culturally sensitive’

The translation and adaptation of a Canadian palliative care decision-making booklet for patients with dementia and their families into Italian, Dutch, and Japanese reveals several culturally sensitive topics, show study results.

14 Nov 2012

IDMC reviews data from Nanobiotix’s NBTXR3 Phase I study on advanced soft tissue sarcoma

Nanobiotix, announced today that the Independent Data Monitoring Committee (IDMC) has reviewed the data of the first 6 patients treated in the phase I Study with the lead product NBTXR3 for the treatment of advanced Soft Tissue Sarcoma of the extremity. Based on the review of the safety data, the IDMC has unanimously recommended continuing the enrollment in the study according to the protocol. This trial is realized in the Institut Gustave Roussy, France.

13 Nov 2012

SCCA to raise awareness about importance of lung cancer screening

Lung cancer is the No. 1 cause of cancer deaths in the United States, despite the fact it is largely preventable. For people at high risk of developing lung cancer, such as current or former longtime smokers, screening for the disease with low-dose CT scans is now a viable option that has been shown to significantly reduce mortality rates. In conjunction with National Lung Cancer Awareness Month, Seattle Cancer Care Alliance (SCCA) wants to raise awareness about the importance of prevention and early detection for at-risk populations.

9 Nov 2012

Mayo Clinic receives FDA approval for Choline C 11 Injection to help detect prostate cancer

Mayo Clinic has received U.S. Food and Drug Administration approval to produce and administer Choline C 11 Injection, an imaging agent used during a positron emission tomography (PET) scan to help detect sites of recurrent prostate cancer. Mayo Clinic is the first, and currently only, institution in North America approved to produce this imaging agent.

9 Nov 2012

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Researchers discover LSD-1 enzyme as important target for treatment of Ewing sarcoma

Two new studies explore how laws, advertising impact cancer costs

mRNA vaccines offer protection against influenza A virus infections in various animal models

Factors influencing pain in head and neck cancer patients clarified

Homing beacon drugs can kill cancer cells

Exercise relieves cancer fatigue

Fujirebio, Thermo Fisher sign license agreement for broad availability of PCT testing

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

Postprostatectomy urinary function assessment tool refined

EMUC discusses current and future prospects in imaging for prostate cancer

Loyola explores different prostate cancer websites for meaningful medical information

Peak interest in health issues comes at about age 51 for baby boomers

Adequate pain management at end of life is a team effort

Promising new minimally toxic approach to treat solid tumors with radiation

Simple ways to reduce risk of lung cancer

Viruses to treat metastatic cancers

Palliative care advice for dementia ‘culturally sensitive’

IDMC reviews data from Nanobiotix’s NBTXR3 Phase I study on advanced soft tissue sarcoma

SCCA to raise awareness about importance of lung cancer screening

Mayo Clinic receives FDA approval for Choline C 11 Injection to help detect prostate cancer

What to know about prostate cancer eBook

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Newsletters you may be interested in